Potentially Inappropriate Medications Are Associated with Increased Healthcare Utilization and Costs
BACKGROUND/OBJECTIVES To examine the prevalence of potentially inappropriate medication (PIM) prescribing and its association with healthcare utilization and related expenditures utilizing nationally representative data from the United States. DESIGN Retrospective cohort study. SETTING The 2011–2015...
Saved in:
Published in: | Journal of the American Geriatrics Society (JAGS) Vol. 68; no. 11; pp. 2542 - 2550 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken, USA
John Wiley & Sons, Inc
01-11-2020
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BACKGROUND/OBJECTIVES
To examine the prevalence of potentially inappropriate medication (PIM) prescribing and its association with healthcare utilization and related expenditures utilizing nationally representative data from the United States.
DESIGN
Retrospective cohort study.
SETTING
The 2011–2015 Medical Expenditure Panel Survey (MEPS).
PARTICIPANTS
Community‐dwelling sample of U.S. adults aged 65 and older during the first round of each MEPS cycle.
MEASUREMENTS
A qualified definition operationalized from the 2019 American Geriatrics Society Beers Criteria® was used to estimate the prevalence of PIM prescribing over the study period. Negative binomial models were assembled to examine associations between PIM exposure and healthcare utilization including hospitalizations, emergency department (ED) visits, and outpatient provider visits. Generalized linear models with the log link function and gamma distribution were used to analyze associations between PIM exposure and healthcare expenditures. Sensitivity analyses were conducted utilizing inverse probability treatment weighting using propensity scores for being prescribed a PIM.
RESULTS
The period prevalence of PIM prescribing over the 5‐year sample was 34.4%. PIM prescribing was positively associated with hospitalizations (adjusted incidence rate ratio [aIRR] = 1.17; 95 confidence interval [CI] = 1.08–1.26; P < .001), ED visits (aIRR = 1.26; 95% CI = 1.17–1.35; P < .001), and outpatient provider visits (aIRR = 1.18; 95% CI = 1.14–1.21; P < .001). PIM exposure was associated with higher marginal costs within outpatient visits ($116; 95% CI = $105–$243; P < .001), prescription medications ($128; 95% CI = $72–$199; P < .001), and total healthcare expenditures ($458; 95% CI = $295–$664; P < .001). Similar results were found in our propensity score analyses.
CONCLUSION
PIMs continue to be prescribed at a high rate among older adults in the United States. Our results suggest that receipt of PIMs is associated with higher rates of healthcare utilization and increased costs across the healthcare continuum. Further work is needed to implement evidence‐based deprescribing interventions that may in turn reduce unnecessary healthcare utilization. |
---|---|
Bibliography: | Previous presentation: These results were previously presented at the American College of Clinical Pharmacy Annual Meeting, October 26, 2019, New York, NY. Author Contributions: Study concept and design: Clark, Wahler, and Jacobs. Acquisition of data: Clark, Feuerstein, and Jacobs. Analysis and interpretation of data: Clark, Shaver, Aurelio, and Jacobs. Drafting of the manuscript: Clark and Jacobs. Critical revision of manuscript for important intellectual content: Shaver, Aurelio, Feuerstein, Wahler, and Daly. Final approval of the version to be published: All authors. |
ISSN: | 0002-8614 1532-5415 |
DOI: | 10.1111/jgs.16743 |